<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688853</url>
  </required_header>
  <id_info>
    <org_study_id>TEG002_MM_US_01</org_study_id>
    <nct_id>NCT04688853</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients</brief_title>
  <official_title>A Phase I Study to Investigate the Safety, Tolerability and Preliminary Efficacy of TEG002 Infusion in Relapsed/Refractory Multiple Myeloma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gadeta B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gadeta B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, multicenter phase I study to assess the safety,&#xD;
      tolerability and preliminary efficacy of autologous T cells transduced with a specific γδTCR,&#xD;
      i.e. TEG002, in a dose escalation and expansion study in relapsed/refractory Multiple Myeloma&#xD;
      patients.&#xD;
&#xD;
      The study will comprise of a Dose Escalation Segment and an Expansion Segment. The study&#xD;
      consists of a screening period, leukapheresis of mononuclear cells, and conditioning&#xD;
      chemotherapy, followed by TEG002. All subjects continue to be followed regularly for safety&#xD;
      and efficacy assessments until 1 year after TEG002 administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety determined by incidence of (S)AEs by type and grade, including the occurrence of dose-limiting toxicities (DLTs)</measure>
    <time_frame>Until day 28 following infusion</time_frame>
    <description>For the dose escalation segment: Safety determined by incidence of (S)AEs by type and grade, including the occurrence of dose-limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: For the expansion segment: Confirmation of safety determined by the incidence of (S)AEs by type and grade</measure>
    <time_frame>Until year 2</time_frame>
    <description>For the expansion segment: Confirmation of safety determined by the incidence of (S)AEs by type and grade</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of TEG002 generation in r/r MM patients as measured by the number of TEG002 products successfully generated in r/r MM patients</measure>
    <time_frame>Assessment per subject production run, timeframe: prior to day 0 for each subject</time_frame>
    <description>Feasibility of TEG002 generation in r/r MM patients as measured by the number of TEG002 products successfully generated in r/r MM patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TEG002 efficacy by looking at Objective response rate</measure>
    <time_frame>Until Year 2</time_frame>
    <description>Efficacy: Objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TEG002 efficacy by looking at Overall survival</measure>
    <time_frame>Until Year 2</time_frame>
    <description>Efficacy: Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TEG002 efficacy by looking at Progression free survival</measure>
    <time_frame>Until Year 2</time_frame>
    <description>Efficacy: Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TEG002 efficacy by looking at Duration of response</measure>
    <time_frame>Until Year 2</time_frame>
    <description>Efficacy: Duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TEG002 efficacy by looking at Time to response</measure>
    <time_frame>Until Year 2</time_frame>
    <description>Efficacy: Time to response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TEG002 efficacy by looking at Time to progression</measure>
    <time_frame>Until Year 2</time_frame>
    <description>Efficacy: Time to progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TEG002 pharmacokinetics measured in blood in bone marrow over time</measure>
    <time_frame>Until Year 2</time_frame>
    <description>Safety &amp; Efficacy: TEG002 persistence measured by qPCR in blood in bone marrow over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TEG002 pharmacodynamics as measured by IL6 level in serum over time</measure>
    <time_frame>until Year 2</time_frame>
    <description>Safety &amp; Efficacy: TEG002 pharmacodynamics measured by the level of IL6 in serum over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TEG002 pharmacodynamics as measured by CRP level in serum over time</measure>
    <time_frame>until Year 2</time_frame>
    <description>Safety &amp; Efficacy: TEG002 pharmacodynamics measured by the CRP level in serum over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TEG002 pharmacodynamics as measured by ferritin level in serum over time</measure>
    <time_frame>until Year 2</time_frame>
    <description>Safety &amp; Efficacy: TEG002 pharmacodynamics measured by the ferritin level in serum over time</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Multiple Myeloma, Refractory</condition>
  <condition>Multiple Myeloma in Relapse</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Single Arm, Open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single arm, open-label, multicenter phase I study with a dose escalation and an expansion segment.&#xD;
For the Dose escalation segment, 3-9 patients per dose cohort will receive:&#xD;
Dose level 1: Low&#xD;
Dose level 2: Medium&#xD;
Dose level 3: High&#xD;
For the expansion segment, additional patients may be enrolled until a maximum of 20 patients have received the recommended dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TEG002</intervention_name>
    <description>TEG002 cells are autologous T cells transduced with a specific γδTCR</description>
    <arm_group_label>Single Arm, Open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Adult&#xD;
&#xD;
          -  Relapsed or refractory Multiple Myeloma as defined by the IMWG&#xD;
&#xD;
          -  Life expectancy ≥3 months&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Adequate vital organ function&#xD;
&#xD;
          -  Adequate bone marrow function&#xD;
&#xD;
          -  Toxicities from prior/ongoing therapies recovered to ≤ Grade 2 or subject's baseline&#xD;
&#xD;
          -  WCBP and men who can father children must be willing and able to use adequate&#xD;
             contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any uncontrolled medical or psychiatric disorder that would preclude participation as&#xD;
             outlined&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Amyloidosis&#xD;
&#xD;
          -  Uncontrolled infection(s)&#xD;
&#xD;
          -  Active CNS disease&#xD;
&#xD;
          -  Previous allogeneic-HSCT&#xD;
&#xD;
          -  History of another primary malignancy that requires intervention beyond surveillance&#xD;
             or that has not been in remission for at least 1 year.&#xD;
&#xD;
          -  Subjects that received experimental or systemic therapy &lt; 14 days before TEG002&#xD;
             infusion&#xD;
&#xD;
          -  NYHA Class ≥ II&#xD;
&#xD;
          -  Patients depending on dialysis&#xD;
&#xD;
          -  Patients with a history of pulmonary embolism or deep vein thrombosis&#xD;
&#xD;
          -  T cell mediated active autoimmune disease OR any active autoimmune disease requiring&#xD;
             immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kirsty van Nierop</last_name>
    <phone>+31850164445</phone>
    <email>k.vannierop@gadeta.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsy Valles</last_name>
      <phone>617-643-9072</phone>
      <email>bvalles@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Branagan, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Logan</last_name>
      <phone>617-667-5984</phone>
      <email>EKLogan@BIDMC.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>David Avigan, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denbaa Bat-Erdene</last_name>
      <phone>617-582-9565</phone>
      <email>Denbaa_Bat-Erdene@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Sperling, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T cell therapy</keyword>
  <keyword>Engineered T Cells</keyword>
  <keyword>TEG</keyword>
  <keyword>TEGs</keyword>
  <keyword>TEG002</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

